Mechanism of FGF receptor dimerization and activation

Nature Communications

Volumn 7, Issue , 2016, Pages

  Sarabipour, Sarvenaz ^a   Hristova, Kalina ^a  

^a Johns Hopkins University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; PHOSPHOTRANSFERASE; LIGAND; PROTEIN BINDING;

CHEMICAL REACTION; CHEMORECEPTION; ENZYME ACTIVITY; LIGAND; MEMBRANE; MUTATION; PATHOGEN; SEPARATION;

ANIMAL CELL; ARTICLE; CHO CELL LINE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIMERIZATION; ENZYME PHOSPHORYLATION; FEMALE; GENE ACTIVATION; HUMAN; LIGAND BINDING; MUTATION; NONHUMAN; PROTEIN DOMAIN; AMINO ACID SEQUENCE; ANIMAL; CELL MEMBRANE; CHEMISTRY; CRICETULUS; GENE EXPRESSION REGULATION; METABOLISM; PLASMID;

AMINO ACID SEQUENCE; ANIMALS; CELL MEMBRANE; CHO CELLS; CRICETULUS; DIMERIZATION; GENE EXPRESSION REGULATION; LIGANDS; MUTATION; PLASMIDS; PROTEIN BINDING; RECEPTORS, FIBROBLAST GROWTH FACTOR;

EID: 84953331204     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10262     Document Type: Article

References (69)

1. Wilkie, A. O. M., Morriss-Kay, G. M., Jones, E. Y., Heath, J. K. Functions of fibroblast growth factors and their receptors. Curr. Biol. 5, 500-507 (1995).
2. Eswarakumar, V. P., Lax, I., Schlessinger, J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16, 139-149 (2005).
3. Ornitz, D. M. FGFs, heparan sulfate and FGFRs: complex interactions essential for development. BioEssays 22, 108-112 (2000).
4. Ornitz, D. M., Itoh, N. Fibroblast growth factors. Genome Biol. 2 (2001).
5. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-921 (1996).
6. Vajo, Z., Francomano, C. A., Wilkin, D. J. The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crouzon syndrome with acanthosis nigricans. Endocr. Rev. 21, 23-39 (2000).
7. Wilkie, A. O. M. Bad bones, absent smell, selfish testes: The pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev. 16, 187-203 (2005).
8. van Rhijn, B. W. G. et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur. J. Hum. Genet. 10, 819-824 (2002).
9. van Rhijn, B. W. G., Montironi, R., Zwarthoff, E. C., Jobsis, A. C., van der Kwast, T. H. Frequent FGFR3 mutations in urothelial papilloma. J. Pathol. 198, 245-251 (2002).
10. Chesi, M. et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92, 3025-3034 (1998).
11. Chesi, M. et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16, 260-264 (1997).
12. Seo, A. N. et al. FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer. Virchows Arch. 465, 547-558 (2014).
13. Turner, N. et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 70, 2085-2094 (2010).
14. Xie, L. et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 19, 2572-2583 (2013).
15. Richelda, R. et al. A novel chromosomal translocation t(4;14)(p16.3;q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90, 4062-4070 (1997).
16. Fantl, W. J., Johnson, D. E., Williams, L. T. Signaling by Receptor Tyrosine Kinases. Annu. Rev. Biochem. 62, 453-481 (1993).
17. L'Horte, C. G. M., Knowles, M. A. Cell responses to FGFR3 signaling: growth, differentiation and apoptosis. Exp. Cell Res. 304, 417-431 (2005).
18. Linggi, B., Carpenter, G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol. 16, 649-656 (2006).
19. Schlessinger, J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306, 1506-1507 (2004).
20. Mohammadi, M. et al. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol. Cell. Biol. 16, 977-989 (1996).
21. Spivakkroizman, T. et al. How do heparin and heparan-sulfate activate Fgf-mitogenic activity. Trends Glycosci. Glycotechnol. 7, 447-449 (1995).
22. Spivakkroizman, T. et al. Heparin-induced oligomerization of Fgf molecules is responsible for Fgf receptor dimerization, activation, and cell-proliferation. Cell 79, 1015-1024 (1994).
23. Mohammadi, M., Olsen, S. K., Ibrahimi, O. A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16, 107-137 (2005).
24. Goetz, R., Mohammadi, M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat. Rev. Mol. Cell Biol. 14, 166-180 (2013).
25. Olsen, S. K. et al. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl Acad. Sci. USA 101, 935-940 (2004).
26. Plotnikov, A. N., Schlessinger, J., Hubbard, S. R., Mohammadi, M. Structural basis for FGF receptor dimerization and activation. Cell 98, 641-650 (1999).
27. Schlessinger, J. et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743-750 (2000).
28. Hidai, C. et al. FGF-1 enhanced cardiogenesis in differentiating embryonal carcinoma cell cultures, which was opposite to the effect of FGF-2. J. Mol. Cell. Cardiol. 35, 421-425 (2003).
29. Ahmed, Z. et al. Direct binding of Grb2 SH3 domain to FGFR2 regulates SHP2 function. Cell. Signal. 22, 23-33 (2010).
30. Takeda, M. et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin. Cancer Res. 13, 3051-3057 (2007).
31. Kunii, K. et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68, 2340-2348 (2008).
32. Bryant, M. R., Marta, C. B., Kim, F. S., Bansal, R. Phosphorylation and lipid raft association of fibroblast growth factor receptor-2 in oligodendrocytes. Glia 57, 935-946 (2009).
33. Chen, L. R., Novicky, L., Merzlyakov, M., Hristov, T., Hristova, K. Measuring the energetics of membrane protein dimerization in mammalian membranes. J. Am. Chem. Soc. 132, 3628-3635 (2010).
34. Sarabipour, S., Chan, R. B., Zhou, B., Di Paolo, G., Hristova, K. Analytical characterization of plasma membrane-derived vesicles produced via osmotic and chemical vesiculation. Biochim. Biophys. Acta 1848, 1591-1598 (2015).
35. Del Piccolo, N., Placone, J., Hristova, K. Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization. Biophys. J. 108, 272-278 (2015).
36. Sarabipour, S., Hristova, K. FGFR3 unliganded dimer stabilization by the juxtamembrane domain. J. Mol. Biol. 427, 1705-1714 (2015).
37. Li, E., Placone, J., Merzlyakov, M., Hristova, K. Quantitative measurements of protein interactions in a crowded cellular environment. Anal. Chem. 80, 5976-5985 (2008).
38. Del Piccolo, N., Placone, J., He, L., Agudelo, S. C., Hristova, K. Production of plasma membrane vesicles with chloride salts and their utility as a cell membrane mimetic for biophysical characterization of membrane protein interactions. Anal. Chem. 84, 8650-8655 (2012).
39. Sarabipour, S., Hristova, K. Glycophorin A transmembrane domain dimerization in plasma membrane vesicles derived from CHO, HEK 293 T, and A431 cells. Biochim. Biophys. Acta 1828, 1829-1833 (2013).
40. Chen, L., Placone, J., Novicky, L., Hristova, K. The extracellular domain of fibroblast growth factor receptor 3 inhibits ligand-independent dimerization. Sci. Signal. 3, ra86 (2010).
41. Sarabipour, S., Del Piccolo, N., Hristova, K. Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging forster resonance energy transfer. Acc. Chem. Res. 48, 2262-2269 (2015).
42. Moscatelli, D. High and low affinity binding-sites for basic fibroblast growth-factor on cultured-cells-absence of a role for low affinity binding in the stimulation of plasminogen-activator production by bovine capillary endothelial-cells. J. Cell. Physiol. 131, 123-130 (1987).
43. Evers, T. H., van Dongen, E. M.W. M., Faesen, A. C., Meijer, E.W., Merkx, M. Quantitative understanding of the energy transfer between fluorescent proteins connected via flexible peptide linkers. Biochemistry 45, 13183-13192 (2006).
44. Lin, C. C. et al. Inhibition of basal FGF receptor signaling by dimeric Grb2. Cell 149, 1514-1524 (2012).
45. Ahmed, Z. et al. Grb2 controls phosphorylation of FGFR2 by inhibiting receptor kinase and Shp2 phosphatase activity. J. Cell Biol. 200, 493-504 (2013).
46. Bocharov, E. V. et al. Structure of FGFR3 transmembrane domain dimer: implications for signaling and human pathologies. Structure 21, 2087-2093 (2013).
47. Li, E., Hristova, K. Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 45, 6241-6251 (2006).
48. He, L., Horton, W. A., Hristova, K. The physical basis behind achondroplasia, the most common form of human dwarfism. J. Biol. Chem. 285, 30103-30114 (2010).
49. Chen, F., Degnin, C., Laederich, M. B., Horton, A. W., Hristova, K. The A391E mutation enhances FGFR3 activation in the absence of ligand. Biochim. Biophys. Acta 1808, 2045-2050 (2011).
50. Chen, F. H., Hristova, K. The physical basis of FGFR3 response to fgf1 and fgf2. Biochemistry 50, 8576-8582 (2011).
51. Chen, F., Sarabipour, S., Hristova, K. Multiple consequences of a single amino acid pathogenic RTK mutation: the A391E mutation in FGFR3. PLoS One 8, e56521 (2013).
52. Lemmon, M. A., Treutlein, H. R., Adams, P. D., Brünger, A. T., Engelman, D. M. A dimerization motif for transmembrane alpha-helices. Nat. Struct. Biol. 1, 157-163 (1994).
53. Doura, A. K., Kobus, F. J., Dubrovsky, L., Hibbard, E., Fleming, K. G. Sequence context modulates the stability of a GxxxG-mediated transmembrane helix-helix dimer. J. Mol. Biol. 341, 991-998 (2004).
54. Cymer, F., Veerappan, A., Schneider, D. Transmembrane helix-helix interactions are modulated by the sequence context and by lipid bilayer properties. Biochim. Biophys. Acta 1818, 963-973 (2012).
55. Li, E., Wimley, W. C., Hristova, K. Transmembrane helix dimerization: beyond the search for sequence motifs. Biochim. Biophys. Acta 1818, 183-193 (2012).
56. Russ, W. P., Engelman, D. M. The GxxxG motif: a framework for transmembrane helix-helix association. J. Mol. Biol. 296, 911-919 (2000).
57. Meyers, G. A., Orlow, S. J., Munro, I. R., Przylepa, K. A., Jabs, E. W. Fibroblast-growth-factor-receptor-3 (Fgfr3) transmembrane mutation in Crouzon-syndrome with acanthosis nigricans. Nat. Genet. 11, 462-464 (1995).
58. Li, E., You, M., Hristova, K. FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J. Mol. Biol. 356, 600-612 (2006).
59. Burgess, A. W. et al. An open-and-shut case Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12, 541-552 (2003).
60. Brewer, M. R. et al. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol. Cell 34, 641-651 (2009).
61. Belov, A. A., Mohammadi, M. Grb2, a double-edged sword of receptor tyrosine kinase signaling. Sci. Signal. 5, pe49 (2012).
62. Bell, C. A. et al. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. Mol. Biol. Cell 11, 3589-3599 (2000).
63. Webster, M. K., Donoghue, D. J. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet. 13, 178-182 (1997).
64. Robertson, S. C., Tynan, J. A., Donoghue, D. J. RTK mutations and human syndromes-when good receptors turn bad. Trends Genet. 16, 265-271 (2000).
65. Cohen, M. M. Some chondrodysplasias with short limbs: molecular perspectives. Am. J. Med. Genet. 112, 304-313 (2002).
66. Sarabipour, S., King, C., Hristova, K. Un-induced high-yield bacterial expression of fluorescent proteins. Anal. Biochem. 449, 155-157 (2014).
67. King, C., Sarabipour, S., Byrne, P., Leahy, D. J., Hristova, K. The FRET signatures of non-interacting proteins in membranes: simulations and experiments. Biophys. J. 106, 1309-1317 (2014).
68. He, L., Hristova, K. Pathogenic activation of receptor tyrosine kinases in mammalian membranes. J. Mol. Biol. 384, 1130-1142 (2008).
69. Plotnikov, A. N., Hubbard, S. R., Schlessinger, J., Mohammadi, M. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101, 413-424 (2000).